AB0412 COMPARISON OF THE EFFICACY AND SAFETY OF A PROPOSED BIOSIMILAR MSB11456 WITH TOCILIZUMAB REFERENCE PRODUCT IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED DOUBLE-BLIND STUDY

Abstract

BackgroundMSB11456 is a biosimilar to currently marketed originator tocilizumab. It has demonstrated pharmacologic, safety and immunogenic similarity to the US-licensed and EU-approved tocilizumab in healthy subjects.ObjectivesTo evaluate the efficacy, immunogenicity...